NEW YORK (GenomeWeb) – Biocept today announced an agreement to participate in MultiPlan's national primary preferred provider organization and complementary network.

Under the terms of the agreement, patients in MultiPlan's networks will have access to Biocept's liquid biopsy diagnostic services, effective August 1. MultiPlan is a national healthcare organization under contract with almost 900,000 providers, Biocept said in a statement, adding about 68 million consumers access the healthcare cost management firm's networks.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.